Supercharged donor cells take aim at blood cancers
NCT ID NCT02494167
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests whether specially trained immune cells from a donor can safely target and kill cancer cells in people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after a stem cell transplant. The cells are grown in a lab to recognize four proteins common on these cancer cells. The main goal is to find the safest dose and see if the cells can reduce or control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
donor-derived T cells trained to recognize tumor proteins (WT1, NY-ESO-1, PRAME, Survivin)
What this could lead to
If it works, this could offer a new way to control AML or MDS after a stem cell transplant, potentially reducing the risk of relapse.
What could go wrong
This is an early Phase 1 trial with only 44 participants, so safety and effectiveness are not yet proven. The treatment may cause side effects or fail to shrink the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Hospital
Houston, Texas, 77030, United States
-
Texas Children's Hospital
Houston, Texas, 77030, United States